Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.58 |
| ▸ | CCR3 | P51677 | 3/20 | 0.54 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.53 |
| ▸ | DRD2 | P14416 | 2/20 | 0.48 |
| ▸ | HTR2A | P28223 | 1/20 | 0.48 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
| ▸ | HTR2B | P41595 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LTA4H | P09960 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6415973 | 0.99 | KMT2A (0.57) | KMT2AMEN1CCR3SIGMAR1DRD2 | |
| SCHEMBL6409199 | 0.91 | CCR3 (0.51) | KMT2AMEN1CCR3SIGMAR1KDM4E | |
| SCHEMBL6408894 | 0.89 | CCR3 (0.50) | KMT2AMEN1CCR3SIGMAR1KDM4E | |
| SCHEMBL6409073 | 0.89 | CCR3 (0.50) | KMT2AMEN1CCR3SIGMAR1LTA4H | |
| SCHEMBL6409303 | 0.89 | CCR3 (0.61) | KMT2AMEN1CCR3SIGMAR1DRD2 | |
| Hydrochloric Acid SCHEMBL6412416 | 0.89 | CCR3 (0.50) | KMT2AMEN1CCR3SIGMAR1DRD2 | |
| Hydrochloric Acid SCHEMBL6410465 | 0.88 | CCR3 (0.49) | KMT2AMEN1CCR3SIGMAR1LTA4H | |
| Hydrochloric Acid SCHEMBL6408480 | 0.88 | CCR3 (0.60) | KMT2AMEN1CCR3SIGMAR1DRD2 | |
| Hydrochloric Acid SCHEMBL6408795 | 0.88 | CCR3 (0.49) | KMT2AMEN1CCR3SIGMAR1KDM4E | |
| SCHEMBL6412927 | 0.86 | CCR3 (0.50) | KMT2AMEN1CCR3SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050075326-A1 | Spiro compounds and methods for the modulation of chemokine receptor activity | VIROCHEM PHARMA INC (CA) | 2005-04-07 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075326-A1 | Spiro compounds and methods for the modulation of chemokine receptor activity | CXCR1, CXCR4, CXCR2 | KMT2A 4587/4885MEN1 4007/4885CCR3 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.